What is Telescope Innovations Corp.'s (TELI.CN) StockRank?

MoatMap's StockRank for Telescope Innovations Corp. (TELI.CN) is 40/100, with a Hold signal. This is a composite score combining Quality (39), Value (23), and Momentum (69) factor ranks across MoatMap's 20,000+ stock universe.

Does Telescope Innovations Corp. have an economic moat?

Telescope Innovations Corp. (TELI.CN) has a Quality factor score of 39/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Telescope Innovations Corp. a buy, hold, or sell?

MoatMap's current signal for Telescope Innovations Corp. (TELI.CN) is Hold, based on a StockRank of 40/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Telescope Innovations Corp. in?

Telescope Innovations Corp. (TELI.CN) operates in the Healthcare sector, specifically the Biotechnology industry (Canada).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

TELI.CN

HOLDREMOVE

Telescope Innovations Corp. · Healthcare · Canada · $49M · Avg Vol: $95K/d

StockRank

P/E (TTM)

—

ROE

-120.5%

D/E

0.6x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Telescope Innovations is a micro-cap chemical automation company that lacks the scale, commercial validation, and liquidity required for our portfolio.

COMPANY DESCRIPTION

Telescope Innovations Corp. is a chemical technology company developing scalable manufacturing processes for pharmaceuticals and critical materials. The company utilizes automation, robotics, and machine learning to optimize chemical synthesis, with a specific focus on therapeutics like psychedelics and advanced materials. Telescope's proprietary technology platform serves as a high-margin B2B service for pharmaceutical and chemical developers.

FINANCIAL SUMMARY (USD)

Year	2021	2022	2023	2024	2025	CAGR
Revenue	—	0.4M	2.0M	3.0M	3.4M	100.2%
EPS	—	-0.08	-0.01	-0.01	-0.02	—
Shares	—	48.8M	53.7M	53.7M	53.7M	+10.1%
Debt	—	1.0M	0	1.4M	2.4M	36.8%
Equity	—	1.2M	1.8M	1.1M	1.4M	6.2%
Op CF	—	-1.0M	-1.2M	13,974	0.2M	1173.0%
Inv CF	—	-0.8M	-25,241	-27,949	-0.7M	—
Fin CF	—	0	1.0M	0	2.1M	—

PRICE (1Y)-2.5%

SMA 50SMA 200

$0.55

RSI (14)

43.1

52W High

$0.78

From 52W High

0.7%

SCORE BREAKDOWN

Quality

ROIC

-31.8%22.0

ROE

-120.5%6.6

GP/Assets

96.4%97.1

Op. Margin

-89.1%17.6

FCF/Assets

-59.1%3.4

Piotroski

675.1

Int. Cover

-5.2x28.0

D/E Ratio

0.58x28.6

Current Ratio

3.33x57.7

Value

P/E (TTM)

—N/A

EV/EBITDA

-29.4x25.0

P/FCF

—N/A

P/B

14.4x7.7

P/S

9.7x26.8

Div Yield

—N/A

Momentum

52W High %

71%73.8

RS 6M

121%98.3

SMA 50/200

1.50x98.3

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$49M

P/E (Forward)

—

Gross Margin

100.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TELI.CN are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
TELI.CN	Telescope Innovations Corp.(you)	$49M	40	HOLD
EDSA	Edesa Biotech, Inc.	$61M	17	STRONG SELL
OBI.L	Ondine Biomedical Inc.	$101M	20	SELL
PMN	ProMIS Neurosciences, Inc.	$97M	15	STRONG SELL
QNTM.CN	Quantum BioPharma Ltd.	$45M	2	STRONG SELL
MSLE	Satellos Bioscience Inc.	$119M	10	STRONG SELL
ENGN	enGene Therapeutics Inc.	$114M	8	STRONG SELL
MDNA.TO	Medicenna Therapeutics Corp.	$27M	1	STRONG SELL
EPRX.TO	Eupraxia Pharmaceuticals Inc.	$415M	26	SELL
MIST	Milestone Pharmaceuticals Inc.	$161M	1	STRONG SELL

Peer medians: ROE -42.2% · P/E 14.3x · Gross margin 32.9%

Telescope Innovations Corp. (TELI.CN) — Stock Score Summary

Telescope Innovations Corp. (TELI.CN) has a MoatMap StockRank of 40/100 based on Quality (39/100), Value (23/100), and Momentum (69/100) factor scores. The current signal is HOLD. Telescope Innovations is a micro-cap chemical automation company that lacks the scale, commercial validation, and liquidity required for our portfolio.

Key Financial Metrics

Price	$0.55
Market Cap	$49M
Price/Book	14.41
Return on Equity	-120.5%
Return on Invested Capital	-31.8%
Debt/Equity	57.95
Gross Margin	100.0%
Operating Margin	-89.1%
Revenue Growth	108.2%
Free Cash Flow	$-3M

Telescope Innovations Corp. operates in the Biotechnology industry, part of the Healthcare sector (Canada).

Frequently Asked Questions

What is Telescope Innovations Corp.’s (TELI.CN) StockRank?: MoatMap’s StockRank for Telescope Innovations Corp. (TELI.CN) is 40/100, with a Hold signal. It is a composite of Quality (39), Value (23), and Momentum (69) factor ranks across MoatMap’s 20,000+ stock universe.
Does Telescope Innovations Corp. have an economic moat?: Telescope Innovations Corp. (TELI.CN) has a Quality factor score of 39/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Telescope Innovations Corp. a buy, hold, or sell?: MoatMap’s current signal for Telescope Innovations Corp. (TELI.CN) is Hold, based on a StockRank of 40/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Telescope Innovations Corp. in?: Telescope Innovations Corp. (TELI.CN) operates in the Healthcare sector, specifically the Biotechnology industry (Canada).